US4340592A - Nutrient compositions and method of administering the same - Google Patents
Nutrient compositions and method of administering the same Download PDFInfo
- Publication number
- US4340592A US4340592A US06/227,127 US22712781A US4340592A US 4340592 A US4340592 A US 4340592A US 22712781 A US22712781 A US 22712781A US 4340592 A US4340592 A US 4340592A
- Authority
- US
- United States
- Prior art keywords
- glycine
- nutrient composition
- mammal
- administering
- aqueous solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
Definitions
- This invention relates to nutrient compositions for mammals and more particularly to nutrient compositions containing oligopeptides and methods of administering them to mammals.
- Man and other mammals require protein daily to satisfy vital functions. Proteins are converted to amino acids in the digestive system and the resulting amino acids are employed by the body for growth, development, multiplication and metabolic functions.
- the human body requires a daily supply of the essential amino acids which are lysine, leucine, isoleucine, tryptophan, methionine, valine, phenylalanine, and threonine.
- the non-essential amino acids are alanine, glycine, serine, proline, histidine, tyrosine and cysteine.
- the body can matabolize amino acids
- the body's transport system can more effectively utilize peptides which can be absorbed and thereafter hydrolyzed within the body's cells to amino acids.
- the peptide transport system has the following features:
- the elemental diets employing free amino acids are usually hypertonic.
- the hypertonicity creates secondary problems in medical patients with gastrointestinal disorders.
- a nutrient composition which is an aqueous solution of oligopeptides (dipeptides and/or tripeptides) wherein each of the oligopeptides has a glycine residue as the N-terminal amino acid grouping.
- the aqueous solution of oligopeptides can be supplied at twice (in the case of dipeptides) or three times (in the case of tripeptides) the concentration of amino acids at the same osmolality as a corresponding solution of free amino acids.
- the oligopeptides are readily assimilated by the transport system and readily converted to amino acid residues.
- the oligopeptides of this invention have a glycine grouping as the N-terminal grouping of the oligopeptides.
- the glycine terminated oligopeptides achieve a desirable intact transport of the oligopeptide into a cell.
- the glycine grouping protects the oligopeptide from hydrolysis into amino acids by the peptidases on a cell membrane. Premature hydrolysis of the oligopeptide into amino acids would upset the osmolality of the system.
- the glycine grouping is also lipophilic and the oligopeptide has an enhanced transport through the cell membrane.
- the oligopeptide can be cleaved into its component amino acids inside the body cell.
- the glycine-terminated oligopeptides are particularly water-soluble which permits the use of such oligopeptides in high concentrations. This feature is of special importance in treating patients having a restricted-water diet, e.g., certain heart patients and kidney patients.
- the glycine-terminated oligopeptides have good thermal stability which permits the autoclaving of such materials for sterilization.
- the glycine-terminated oligopeptides in solution also have good shelf-life stability.
- the oligopeptides may be administered intravenously, along with other nutrient compositions such as fats, glucose, saccharides, minerals, trace elements and vitamins.
- the oligopeptide solution may be introduced orally or by other intragastrointestinal administration techniques, e.g., stomach tubes and insertion tubes elsewhere in the intestinal tract.
- the oligopeptide solution contains from about one to twenty percent by weight of the oligopeptides, preferably about one to five percent by weight.
- the aqueous solution may be an electrolyte solution suitable for intravenous feeding or for intragastrointestinal administration.
- the aqueous solution itself may contain the other nutrient additives such as fats, glucose, mono- or oligo saccharides, minerals, trace elements and vitamins.
- Aqueous dietary compositions are prepared which include at least two tripeptides or at least two dipeptides or mixtures containing at least one dipeptide and at least one tripeptide.
- the oligopeptides include a glycine residue and one or two other essential amino acid residues such as lysine, leucine, isoleucine, tryptophan, methionine, valine, phenylalanine, threonine; or non-essential amino acids such as arginine, histidine, alanine, proline and glutamic acid.
- the glycine residue is the N-terminal residue in the oligopeptide.
- the concentration of the oligopeptide in the aqueous solution is from 1 to 20 percent by weight, preferably from 1 to 5 percent by weight.
- Aqueous solutions containing about 2.5 weight percent of the oligopeptides have useful biological absorption characteristics.
- the selection of the oligopeptides in the composition depends upon the requirements for essential and non-essential amino acids.
- the mixture of Table 1 is intended to approximate one 850-mg. portion of a protein of high biological value.
- the mixture of Table 1 in one liter of water, comprises a useful nutrient composition.
- the first eight tripeptides of Table 1 provide all of the essential amino acids.
- the glycine-alanine-alanine tripeptide satisfies a need for non-essential amino acids.
- the glycine unit ##STR2## supplies the N-terminal grouping in the tripeptide or dipeptide.
- a composition of dipeptides is provided in Table 2 for preparing a one-liter aqueous solution of dipeptides which supplies the human daily amino acid requirements. It will be observed that the dipeptides include a glycine residue which is the N-terminal residue.
- the aqueous oligopeptide solution may be ingested orally along with other nutrients such as conventional foods of prepared vitamins, fats, glucose, oligosaccharides, minerals and trace elements.
- a supply of the oligopeptide solution may be merged through a Y-connection with a supply of glucose solution or other parenteral solutions.
- the oligopeptide solution may be mixed with glucose solutions and/or other parenteral solutions to create a mixture which may be administered parenterally.
- oligopeptide mixture for oral use can also be used for parenteral nutrition.
- situations are encountered in which patients are unable to receive their daily nutrient requirements orally.
- the development of total parenteral nutrition by Dudrick and colleagues (Dudrick et al, Surgery 64:134-142, 1968) has made possible the intravenous infusion of sufficient energy and essential nutrient requirements.
- the intravenous solutions currently used are made up of free amino acids which made these solutions hypertonic. Therefore, the solutions must be given through catheters placed in large central veins, frequently considered to be a surgical procedure. Serious complications, such as infection, have been reported to accompany this central vein method of parenteral nutrition.
- oligopeptides rather than free amino acids allows administration of the same amount of amino acid residue in solutions which are not hypertonic and therefore can be introduced into peripheral veins, which procedure is not considered to be a surgical procedure.
- the concentration of the oligopeptides in an intravenous solution should be such that the amino acid composition of the solution is similar to the amino acid composition of the currently-used free amino acid solution which has shown to be satisfactory for maintaining protein nutrition.
- the oligopeptides of the present compositions are water-soluble.
- the composition preferably contains some oligopeptides of non-essential amino acids to supply nitrogen.
- the composition permits intact transportation of the oligopeptide into the cells followed by intra-cellular hydrolysis.
- Intravenous injection of the oligopeptides results in an increase in the insulin output when compared with the output resulting from intravenous injection of corresponding free amino acids.
- the oligopeptides rapidly disappear following intravenous injection, indicating that they are rapidly utilized.
- the speed of utilization is particularly rapid with kidney tissue; less rapid with muscle tissue.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
TABLE 1 ______________________________________ One 850-mg. Portion Tripeptides Amount (mg) ______________________________________ glycine-leucine-leucine 77 glycine-isoleucine-isoleucine 59 glycine-valine-valine 70 glycine-threonine-threonine 53 glycine-methionine-methionine 71 glycine-phenylalanine-phenylalanine 75 glycine-lysine-lysine 57 glycine-tryptophan-tryptophan 21 glycine-alanine-alanine 367 ______________________________________
TABLE 2 ______________________________________ One liter Solution Dipeptide grams ______________________________________ glycine-isoleucine 2.5 glycine-leucine 3.5 glycine-lysine 3.1 glycine-methionine 3.2 glycine-phenylalanine 3.3 glycine-threonine 1.6 glycine-tryptophan 0.63 glycine-valine 2.5 glycine-arginine 5.9 glycine-histidine 1.5 glycine-alanine 5.4 glycine-glutamic acid 6.9 glycine-proline 5.8 ______________________________________
Claims (12)
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US06/227,127 US4340592A (en) | 1980-03-14 | 1981-01-26 | Nutrient compositions and method of administering the same |
GB8106648A GB2071670B (en) | 1980-03-14 | 1981-03-03 | Nutrient compositions and methods of administering the same |
FR8104278A FR2477843A1 (en) | 1980-03-14 | 1981-03-04 | NUTRIENTS AND METHOD OF ADMINISTRATION |
DE3108079A DE3108079C2 (en) | 1980-03-14 | 1981-03-04 | Nutriensolution containing aqueous oligopeptides |
CH160081A CH646874A5 (en) | 1980-03-14 | 1981-03-09 | NUTRITIONAL SOLUTION. |
NL8101182A NL190951C (en) | 1980-03-14 | 1981-03-11 | Nutritional composition comprising a peptides-containing aqueous solution. |
SE8101585A SE454746B (en) | 1980-03-14 | 1981-03-12 | NUTRITIONAL COMPOSITION CONCERNING A WATER SOLUTION CONTAINING FROM 1 TO 20 WEIGHT PERCENTAGE OF AT LEAST TWO Oligopeptides, SELECTED DIPEPTIDES AND TRIPEPTIDES |
AU68338/81A AU543401B2 (en) | 1980-03-14 | 1981-03-13 | Nutrient compostions |
AT0117581A AT372281B (en) | 1980-03-14 | 1981-03-13 | METHOD FOR PRODUCING A NUTRIENS CONNECTION |
CA000373100A CA1173692A (en) | 1980-03-14 | 1981-03-16 | Nutrient compositions and method of administering the same |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13030980A | 1980-03-14 | 1980-03-14 | |
US06/227,127 US4340592A (en) | 1980-03-14 | 1981-01-26 | Nutrient compositions and method of administering the same |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13030980A Continuation-In-Part | 1980-03-14 | 1980-03-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
US4340592A true US4340592A (en) | 1982-07-20 |
Family
ID=26828352
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US06/227,127 Expired - Lifetime US4340592A (en) | 1980-03-14 | 1981-01-26 | Nutrient compositions and method of administering the same |
Country Status (9)
Country | Link |
---|---|
US (1) | US4340592A (en) |
AT (1) | AT372281B (en) |
AU (1) | AU543401B2 (en) |
CH (1) | CH646874A5 (en) |
DE (1) | DE3108079C2 (en) |
FR (1) | FR2477843A1 (en) |
GB (1) | GB2071670B (en) |
NL (1) | NL190951C (en) |
SE (1) | SE454746B (en) |
Cited By (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1985003869A1 (en) * | 1984-03-01 | 1985-09-12 | Vernon Erk | Method of treating memory disorders of the elderly |
WO1985003873A1 (en) * | 1984-03-01 | 1985-09-12 | Vernon Erk | Method of treating hypertension in vertebrates |
WO1985003872A1 (en) * | 1984-03-01 | 1985-09-12 | Vernon Erk | Method of lowering blood sugar level in vertebrates |
WO1985003870A1 (en) * | 1984-03-01 | 1985-09-12 | Vernon Erk | A method of treating hypoglycemia in vertebrates |
EP0182356A2 (en) * | 1984-11-19 | 1986-05-28 | The Montefiore Hospital Association of Western Pennsylvania | Nutrient compositions |
US4849408A (en) * | 1986-01-18 | 1989-07-18 | (501) Fresenius Ag | Method of treatment of cerebral disturbances with oligopeptides containing tryptophan |
US4948788A (en) * | 1985-09-05 | 1990-08-14 | Teijin Limited | Composition for injection of active type vitamins D3 |
US5034377A (en) * | 1984-11-19 | 1991-07-23 | Montefiore Hospital Association Of Western Pennsylvania | Aqueous nutrient compositions comprising oligopeptides |
US5036052A (en) * | 1988-06-22 | 1991-07-30 | Morishita Pharmaceutical Co., Ltd. | Amino acid nutrient compositions |
EP0457314A1 (en) * | 1990-05-18 | 1991-11-21 | Clintec Nutrition Company | Nutrient compositions containing peptides |
US5122515A (en) * | 1990-06-19 | 1992-06-16 | Smith Ross C | Nutrient composition containing dipeptides and method for administering the same |
US5134125A (en) * | 1989-03-28 | 1992-07-28 | Kyowa Hakko Kogyo Co., Ltd. | Nutrient composition |
US5167957A (en) * | 1990-09-06 | 1992-12-01 | Virginia Tech Intellectual Properties, Inc. | Compositions and methods for the treatment of dietary deficiencies |
US5326569A (en) * | 1992-12-23 | 1994-07-05 | Abbott Laboratories | Medical foods for the nutritional support of child/adult metabolic diseases |
US5378722A (en) * | 1993-12-03 | 1995-01-03 | Clintec Nutrition Co. | Nutritional compositions for management of nitrogen metabolism |
US5432160A (en) * | 1993-01-29 | 1995-07-11 | Kyowa Hakko Kohyo Co., Ltd. | Nutrient composition |
US5550146A (en) * | 1992-12-23 | 1996-08-27 | Abbott Laboratories | Medical foods for the nutritional support of infant/toddler metabolic diseases |
US5576351A (en) * | 1989-12-29 | 1996-11-19 | Mcgaw, Inc. | Use of arginine as an immunostimulator |
US5891459A (en) * | 1993-06-11 | 1999-04-06 | The Board Of Trustees Of The Leland Stanford Junior University | Enhancement of vascular function by modulation of endogenous nitric oxide production or activity |
US6368640B1 (en) | 1998-04-03 | 2002-04-09 | The Daily Wellness Company | Method and composition for improving sexual fitness |
US20020192307A1 (en) * | 1998-04-03 | 2002-12-19 | Wuh Hank C.K. | Method and composition for enhancing sexual desire |
US6497885B2 (en) | 2000-12-22 | 2002-12-24 | The Daily Wellness Company | Method and composition for improving fertility health in female and male animals and humans |
US20040074504A1 (en) * | 1999-06-05 | 2004-04-22 | Cooke John P. | Method and composition for inhibiting cardiovascular cell proliferation |
US20040092429A1 (en) * | 2002-01-29 | 2004-05-13 | Zealand Pharma A/S | Compositions and methods for modulating connexin hemichannels |
US20040097426A1 (en) * | 1999-08-13 | 2004-05-20 | Josef Neu | Dipeptides for prevention of muscle breakdown and microbial infection |
US20050070484A1 (en) * | 2003-09-26 | 2005-03-31 | Josef Neu | Arginyl-glutamine dipeptide for treatment of pathological vascular proliferation |
US20050192210A1 (en) * | 2004-03-01 | 2005-09-01 | Rothbard Jonathan B. | Compositions and methods for treating diseases |
US6989164B2 (en) | 2000-12-22 | 2006-01-24 | The Daily Wellness Company | Method and composition for improving male fertility health |
US20060229256A1 (en) * | 2003-09-26 | 2006-10-12 | Bristol-Myers Squibb Company | Enternal administration of arginine and glutamine for abnormal vascular proliferation |
US7371415B1 (en) | 1998-04-03 | 2008-05-13 | The Daily Wellness Company | Method and composition for improving sexual fitness |
US20080305151A1 (en) * | 2005-09-20 | 2008-12-11 | Kyowa Hakko Kogyo Co., Ltd. | Dipeptide-Comprising Composition for Oral Administration |
US20090124560A1 (en) * | 2006-04-21 | 2009-05-14 | Masashi Morifuji | Composition Containing Peptide as Active Ingredient |
US20130189715A1 (en) * | 2009-02-27 | 2013-07-25 | Medical Diagnostic Laboratories, Llc | Hemolysin and its Protein Fragments in Sero-Detection of Anaplasma Phagocytophilum |
US20140349323A1 (en) * | 2006-09-12 | 2014-11-27 | Hoffmann-La Roche Inc. | Anti-drug antibody assay |
US8940791B2 (en) | 2005-11-11 | 2015-01-27 | Signature R&D Holdings, Llc | Acetylated amino acids as anti-platelet agents, nutritional and vitamin supplements |
CN107744140A (en) * | 2017-11-06 | 2018-03-02 | 威海红印食品科技有限公司 | A kind of predigestion type pancebrin and preparation method thereof |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3206784C2 (en) * | 1982-02-25 | 1985-05-09 | Pfrimmer & Co Pharmazeutische Werke Erlangen Gmbh, 8520 Erlangen | Glutamine-containing preparations for oral or intravenous administration |
DE4022267C2 (en) * | 1990-07-12 | 1994-09-15 | Degussa | N-acyl dipeptides and their use |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4095000A (en) * | 1974-05-17 | 1978-06-13 | Max Brenner | Protein-saving foodstuff and fodder additive |
US4127534A (en) * | 1977-06-16 | 1978-11-28 | Coy David Howard | Novel tripeptides, intermediates therefor and pharmaceutical compositions and methods employing said tripeptides |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH591918A5 (en) * | 1974-03-05 | 1977-10-14 | Nestle Sa | |
US4024286A (en) * | 1976-05-17 | 1977-05-17 | Miles Laboratories, Inc. | Fortification of foodstuffs with C-terminal amino acid substituted methionine dipeptides |
-
1981
- 1981-01-26 US US06/227,127 patent/US4340592A/en not_active Expired - Lifetime
- 1981-03-03 GB GB8106648A patent/GB2071670B/en not_active Expired
- 1981-03-04 FR FR8104278A patent/FR2477843A1/en active Granted
- 1981-03-04 DE DE3108079A patent/DE3108079C2/en not_active Expired
- 1981-03-09 CH CH160081A patent/CH646874A5/en not_active IP Right Cessation
- 1981-03-11 NL NL8101182A patent/NL190951C/en not_active IP Right Cessation
- 1981-03-12 SE SE8101585A patent/SE454746B/en not_active IP Right Cessation
- 1981-03-13 AU AU68338/81A patent/AU543401B2/en not_active Ceased
- 1981-03-13 AT AT0117581A patent/AT372281B/en not_active IP Right Cessation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4095000A (en) * | 1974-05-17 | 1978-06-13 | Max Brenner | Protein-saving foodstuff and fodder additive |
US4127534A (en) * | 1977-06-16 | 1978-11-28 | Coy David Howard | Novel tripeptides, intermediates therefor and pharmaceutical compositions and methods employing said tripeptides |
Cited By (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1985003873A1 (en) * | 1984-03-01 | 1985-09-12 | Vernon Erk | Method of treating hypertension in vertebrates |
WO1985003872A1 (en) * | 1984-03-01 | 1985-09-12 | Vernon Erk | Method of lowering blood sugar level in vertebrates |
WO1985003870A1 (en) * | 1984-03-01 | 1985-09-12 | Vernon Erk | A method of treating hypoglycemia in vertebrates |
WO1985003869A1 (en) * | 1984-03-01 | 1985-09-12 | Vernon Erk | Method of treating memory disorders of the elderly |
AU598443B2 (en) * | 1984-03-01 | 1990-06-28 | Vernon Erk | A method of treating hypoglycemia in vertebrates |
AU599567B2 (en) * | 1984-03-01 | 1990-07-26 | Vernon Erk | Method of treating memory disorders of the elderly |
US5034377A (en) * | 1984-11-19 | 1991-07-23 | Montefiore Hospital Association Of Western Pennsylvania | Aqueous nutrient compositions comprising oligopeptides |
EP0182356A2 (en) * | 1984-11-19 | 1986-05-28 | The Montefiore Hospital Association of Western Pennsylvania | Nutrient compositions |
EP0182356A3 (en) * | 1984-11-19 | 1989-03-08 | The Montefiore Hospital Association Of Western Pennsylvania | Nutrient compositions nutrient compositions |
US4948788A (en) * | 1985-09-05 | 1990-08-14 | Teijin Limited | Composition for injection of active type vitamins D3 |
US4849408A (en) * | 1986-01-18 | 1989-07-18 | (501) Fresenius Ag | Method of treatment of cerebral disturbances with oligopeptides containing tryptophan |
US5036052A (en) * | 1988-06-22 | 1991-07-30 | Morishita Pharmaceutical Co., Ltd. | Amino acid nutrient compositions |
US5134125A (en) * | 1989-03-28 | 1992-07-28 | Kyowa Hakko Kogyo Co., Ltd. | Nutrient composition |
US5576351A (en) * | 1989-12-29 | 1996-11-19 | Mcgaw, Inc. | Use of arginine as an immunostimulator |
US5189016A (en) * | 1990-05-18 | 1993-02-23 | Clintec Nutrition Co. | Nutrient compositions containing peptides and method for administering the same |
EP0457314A1 (en) * | 1990-05-18 | 1991-11-21 | Clintec Nutrition Company | Nutrient compositions containing peptides |
US5122515A (en) * | 1990-06-19 | 1992-06-16 | Smith Ross C | Nutrient composition containing dipeptides and method for administering the same |
US5167957A (en) * | 1990-09-06 | 1992-12-01 | Virginia Tech Intellectual Properties, Inc. | Compositions and methods for the treatment of dietary deficiencies |
US5587399A (en) * | 1992-12-23 | 1996-12-24 | Abbott Laboratories | Method for preparing medical foods for the nutritional support of infants/toddlers with metabolic diseases |
US5326569A (en) * | 1992-12-23 | 1994-07-05 | Abbott Laboratories | Medical foods for the nutritional support of child/adult metabolic diseases |
US5550146A (en) * | 1992-12-23 | 1996-08-27 | Abbott Laboratories | Medical foods for the nutritional support of infant/toddler metabolic diseases |
US5432160A (en) * | 1993-01-29 | 1995-07-11 | Kyowa Hakko Kohyo Co., Ltd. | Nutrient composition |
US5891459A (en) * | 1993-06-11 | 1999-04-06 | The Board Of Trustees Of The Leland Stanford Junior University | Enhancement of vascular function by modulation of endogenous nitric oxide production or activity |
US7452916B2 (en) * | 1993-06-11 | 2008-11-18 | The Board Of Trustees Of The Leland Stanford Junior University | Enhancement of vascular function by modulation of endogenous nitric oxide production or activity |
US6646006B2 (en) | 1993-06-11 | 2003-11-11 | The Board Of Trustees Of The Leland Stanford Junior University | Enhancement of vascular function by modulation of endogenous nitric oxide production or activity |
US20040082659A1 (en) * | 1993-06-11 | 2004-04-29 | The Board Of Trustees Of The Leland Stanford Junior University | Enhancement of vascular function by modulation of endogenous nitric oxide production or activity |
US20060009407A1 (en) * | 1993-06-11 | 2006-01-12 | The Board Of Trustees Of The Leland Stanford Junior University | Enhancement of vascular function by modulation of endogenous nitric oxide production or activity |
US5378722A (en) * | 1993-12-03 | 1995-01-03 | Clintec Nutrition Co. | Nutritional compositions for management of nitrogen metabolism |
US6368640B1 (en) | 1998-04-03 | 2002-04-09 | The Daily Wellness Company | Method and composition for improving sexual fitness |
US20020192307A1 (en) * | 1998-04-03 | 2002-12-19 | Wuh Hank C.K. | Method and composition for enhancing sexual desire |
US7371415B1 (en) | 1998-04-03 | 2008-05-13 | The Daily Wellness Company | Method and composition for improving sexual fitness |
US6544563B2 (en) | 1998-04-03 | 2003-04-08 | The Daily Wellness Company | Method and composition for improving sexual fitness |
US20030203053A1 (en) * | 1998-04-03 | 2003-10-30 | Wuh Hank C.K. | Method and composition for improving sexual fitness |
US20050196470A9 (en) * | 1998-04-03 | 2005-09-08 | Wuh Hank C | Method and composition for enhancing sexual desire |
US20040074504A1 (en) * | 1999-06-05 | 2004-04-22 | Cooke John P. | Method and composition for inhibiting cardiovascular cell proliferation |
US20060159719A1 (en) * | 1999-06-05 | 2006-07-20 | The Board Of Trustees Of The Leland Stanford Junior University | Method and composition for inhibiting cardiovascular cell proliferation |
US20060167402A1 (en) * | 1999-06-05 | 2006-07-27 | The Board Of Trustees Of The Leland Stanford Junior University | Method and composition for inhibiting cardiovascular cell proliferation |
US8133868B2 (en) | 1999-08-13 | 2012-03-13 | University Of Florida Research Foundation, Inc. | Dipeptides for prevention of muscle breakdown and microbial infection |
US20040097426A1 (en) * | 1999-08-13 | 2004-05-20 | Josef Neu | Dipeptides for prevention of muscle breakdown and microbial infection |
US7855181B2 (en) | 1999-08-13 | 2010-12-21 | University Of Florida Research Foundation, Inc. | Dipeptides for prevention of muscle breakdown and microbial infection |
US20090082283A1 (en) * | 1999-08-13 | 2009-03-26 | Josef Neu | Dipeptides for Prevention of Muscle Breakdown and Microbial Infection |
US20030026851A1 (en) * | 2000-12-22 | 2003-02-06 | Trant Aileen Sontag | Method and composition for improving fertility health in female and male animals and humans |
US7045151B2 (en) | 2000-12-22 | 2006-05-16 | The Daily Wellness Company | Method and composition for improving fertility health in female and male animals and humans |
US6497885B2 (en) | 2000-12-22 | 2002-12-24 | The Daily Wellness Company | Method and composition for improving fertility health in female and male animals and humans |
US6989164B2 (en) | 2000-12-22 | 2006-01-24 | The Daily Wellness Company | Method and composition for improving male fertility health |
US7153822B2 (en) | 2002-01-29 | 2006-12-26 | Wyeth | Compositions and methods for modulating connexin hemichannels |
US20070042964A1 (en) * | 2002-01-29 | 2007-02-22 | Wyeth | Compositions and methods for modulating connexin hemichannels |
US20040092429A1 (en) * | 2002-01-29 | 2004-05-13 | Zealand Pharma A/S | Compositions and methods for modulating connexin hemichannels |
US20060229256A1 (en) * | 2003-09-26 | 2006-10-12 | Bristol-Myers Squibb Company | Enternal administration of arginine and glutamine for abnormal vascular proliferation |
US7148199B2 (en) | 2003-09-26 | 2006-12-12 | University Of Florida Research Foundation, Inc. | Arginyl-glutamine dipeptide for treatment of pathological vascular proliferation |
US20070054866A1 (en) * | 2003-09-26 | 2007-03-08 | Josef Neu | Arginyl-glutamine dipeptide for treatment of pathological vascular proliferation |
US20050070484A1 (en) * | 2003-09-26 | 2005-03-31 | Josef Neu | Arginyl-glutamine dipeptide for treatment of pathological vascular proliferation |
US7754692B2 (en) | 2003-09-26 | 2010-07-13 | University Of Florida Research Foundation, Inc. | Arginyl-glutamine dipeptide for treatment of pathological vascular proliferation |
US7557087B2 (en) | 2004-03-01 | 2009-07-07 | Lumen Therapeutics, Llc | Compositions and methods for treating diseases |
US20070185203A1 (en) * | 2004-03-01 | 2007-08-09 | Rothbard Jonathan B | Compositions and Methods for Treating Diseases |
US20050192210A1 (en) * | 2004-03-01 | 2005-09-01 | Rothbard Jonathan B. | Compositions and methods for treating diseases |
US20080305151A1 (en) * | 2005-09-20 | 2008-12-11 | Kyowa Hakko Kogyo Co., Ltd. | Dipeptide-Comprising Composition for Oral Administration |
US7846902B2 (en) | 2005-09-20 | 2010-12-07 | Kyowa Hakko Bio Co., Ltd. | Dipeptide-comprising composition for oral administration |
US8940791B2 (en) | 2005-11-11 | 2015-01-27 | Signature R&D Holdings, Llc | Acetylated amino acids as anti-platelet agents, nutritional and vitamin supplements |
US20090124560A1 (en) * | 2006-04-21 | 2009-05-14 | Masashi Morifuji | Composition Containing Peptide as Active Ingredient |
US8343531B2 (en) * | 2006-04-21 | 2013-01-01 | Meiji Co., Ltd. | Composition containing peptide as active ingredient |
US20140349323A1 (en) * | 2006-09-12 | 2014-11-27 | Hoffmann-La Roche Inc. | Anti-drug antibody assay |
US9933433B2 (en) * | 2006-09-12 | 2018-04-03 | Hoffmann-La Roche Inc. | Anti-drug antibody assay |
US20130189715A1 (en) * | 2009-02-27 | 2013-07-25 | Medical Diagnostic Laboratories, Llc | Hemolysin and its Protein Fragments in Sero-Detection of Anaplasma Phagocytophilum |
US8859722B2 (en) * | 2009-02-27 | 2014-10-14 | Medical Diagnostic Laboratories, Llc | Hemolysin and its protein fragments in sero-detection of anaplasma phagocytophilum |
CN107744140A (en) * | 2017-11-06 | 2018-03-02 | 威海红印食品科技有限公司 | A kind of predigestion type pancebrin and preparation method thereof |
Also Published As
Publication number | Publication date |
---|---|
CH646874A5 (en) | 1984-12-28 |
GB2071670B (en) | 1983-07-13 |
ATA117581A (en) | 1983-02-15 |
DE3108079A1 (en) | 1982-01-21 |
GB2071670A (en) | 1981-09-23 |
NL8101182A (en) | 1981-10-01 |
AT372281B (en) | 1983-09-26 |
AU6833881A (en) | 1981-09-17 |
DE3108079C2 (en) | 1986-01-16 |
SE454746B (en) | 1988-05-30 |
FR2477843A1 (en) | 1981-09-18 |
NL190951C (en) | 1994-11-16 |
FR2477843B1 (en) | 1985-03-22 |
NL190951B (en) | 1994-06-16 |
AU543401B2 (en) | 1985-04-18 |
SE8101585L (en) | 1981-09-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4340592A (en) | Nutrient compositions and method of administering the same | |
AU682894B2 (en) | Composition based on amino acids intended for the treatment of sepsis or of an attack bringing about an inflammatory reaction, in animals and man | |
US6060446A (en) | Method and composition for treating renal disease and failure | |
Vinnars et al. | History of parenteral nutrition | |
TWI429405B (en) | Pediatric amino acid solution for parenteral nutrition | |
US5189016A (en) | Nutrient compositions containing peptides and method for administering the same | |
CA2089257A1 (en) | Product containing growth factor and glutamine and use of growth factor for the treatment of intestinal mucosa | |
US5747459A (en) | Method for insuring adequate intracellular glutathione in tissue | |
Rérat | Nutritional supply of proteins and absorption of their hydrolysis products: consequences on metabolism | |
EP0502313A2 (en) | Method for insuring adequate intracellular glutathione in tissue | |
Chen et al. | Influence of glutamine-supplemented parenteral nutrition on intestinal amino acid metabolism in rats after small bowel resection | |
CA2134380C (en) | Composition based on amino acids intended for the treatment of sepsis or of an attack bringing about an inflammatory reaction, in animals and man | |
US5122515A (en) | Nutrient composition containing dipeptides and method for administering the same | |
JP4011638B2 (en) | Oral enteral nutrition composition | |
JP3182564B2 (en) | Nutrition composition | |
EP0656178B1 (en) | Nutritional compositions for management of nitrogen metabolism | |
JP2683129B2 (en) | Nutrition composition | |
JPH07330583A (en) | Liquid preparation containing free glutamic acid | |
JP3914585B2 (en) | Macrophage nitric oxide production enhancer | |
JPS6326733B2 (en) | ||
Børresen | Balanced intravenous nutrition in pediatric surgery | |
JP2518636B2 (en) | Enteral nutrition for the treatment of severe infections and widespread fever | |
Yamakawa et al. | Peptide digestion and absorption in humans: Portal vein, hepatic vein, and peripheral venous amino acid concentrations | |
JP3534535B2 (en) | Glutamine-containing nutrient solution | |
RU2045911C1 (en) | Product for enteral nutrition of patients with high metabolic stress "energoplasten" |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FEPP | Fee payment procedure |
Free format text: MAINTENANCE FEE REMINDER MAILED (ORIGINAL EVENT CODE: REM.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
FEPP | Fee payment procedure |
Free format text: SURCHARGE FOR LATE PAYMENT, PL 96-517 (ORIGINAL EVENT CODE: M176); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YEAR, PL 96-517 (ORIGINAL EVENT CODE: M170); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY Year of fee payment: 4 |
|
FEPP | Fee payment procedure |
Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YEAR, PL 96-517 (ORIGINAL EVENT CODE: M171); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY Year of fee payment: 8 |
|
FEPP | Fee payment procedure |
Free format text: SURCHARGE FOR LATE PAYMENT, LARGE ENTITY (ORIGINAL EVENT CODE: M186); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 12TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M185); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY Year of fee payment: 12 |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |